Market open
BeiGene, Ltd/$ONC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About BeiGene, Ltd
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.
Ticker
$ONC
Sector
Trading on
Industry
Biotechnology
Headquarters
Camana Bay, Cayman Islands
Employees
10,600
Website
BeiGene, Ltd Metrics
BasicAdvanced
$24B
-
-$7.86
0.60
-
Price and volume
Market cap
$24B
Beta
0.6
52-week high
$233.50
52-week low
$174.74
Financial strength
Current ratio
1.938
Quick ratio
1.645
Long term debt to equity
6.391
Total debt to equity
30.545
Interest coverage (TTM)
-57.74%
Management effectiveness
Return on assets (TTM)
-9.58%
Return on equity (TTM)
-23.22%
Valuation
Price to revenue (TTM)
7.18
Price to book
0.98
Price to tangible book (TTM)
1.01
Price to free cash flow (TTM)
-19.628
Growth
Revenue change (TTM)
50.22%
Earnings per share change (TTM)
-16.40%
3-year revenue growth (CAGR)
46.66%
3-year earnings per share growth (CAGR)
-17.55%
BeiGene, Ltd News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for BeiGene, Ltd stock?
BeiGene, Ltd (ONC) has a market cap of $24B as of February 12, 2025.
What is the P/E ratio for BeiGene, Ltd stock?
The price to earnings (P/E) ratio for BeiGene, Ltd (ONC) stock is 0 as of February 12, 2025.
Does BeiGene, Ltd stock pay dividends?
No, BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders as of February 12, 2025.
When is the next BeiGene, Ltd dividend payment date?
BeiGene, Ltd (ONC) stock does not pay dividends to its shareholders.
What is the beta indicator for BeiGene, Ltd?
BeiGene, Ltd (ONC) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.